DE19937219A1 - Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie - Google Patents
Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels IonenaustauscherchromatographieInfo
- Publication number
- DE19937219A1 DE19937219A1 DE19937219A DE19937219A DE19937219A1 DE 19937219 A1 DE19937219 A1 DE 19937219A1 DE 19937219 A DE19937219 A DE 19937219A DE 19937219 A DE19937219 A DE 19937219A DE 19937219 A1 DE19937219 A1 DE 19937219A1
- Authority
- DE
- Germany
- Prior art keywords
- protease
- proenzyme
- factor vii
- proteins
- matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000010911 Enzyme Precursors Human genes 0.000 title claims abstract description 57
- 108010062466 Enzyme Precursors Proteins 0.000 title claims abstract description 57
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 27
- 108091005804 Peptidases Proteins 0.000 title claims description 82
- 239000004365 Protease Substances 0.000 title claims description 81
- 108010023321 Factor VII Proteins 0.000 title claims description 16
- 230000003213 activating effect Effects 0.000 title claims description 10
- 230000008569 process Effects 0.000 title claims description 9
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title claims 8
- 239000000203 mixture Substances 0.000 title description 7
- 238000004255 ion exchange chromatography Methods 0.000 title description 2
- 235000018102 proteins Nutrition 0.000 claims abstract description 28
- 239000011159 matrix material Substances 0.000 claims abstract description 21
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000005571 anion exchange chromatography Methods 0.000 claims abstract description 11
- 238000005277 cation exchange chromatography Methods 0.000 claims abstract description 9
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 8
- 229940124272 protein stabilizer Drugs 0.000 claims abstract description 8
- 238000012360 testing method Methods 0.000 claims abstract description 8
- 239000004475 Arginine Substances 0.000 claims abstract description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000012634 fragment Substances 0.000 claims abstract description 6
- 229960002897 heparin Drugs 0.000 claims abstract description 6
- 229920000669 heparin Polymers 0.000 claims abstract description 6
- 150000002500 ions Chemical class 0.000 claims abstract description 6
- 238000001556 precipitation Methods 0.000 claims abstract description 6
- 108010039627 Aprotinin Proteins 0.000 claims abstract description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 5
- 229960004405 aprotinin Drugs 0.000 claims abstract description 5
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 claims abstract description 5
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract description 5
- 239000013522 chelant Substances 0.000 claims abstract description 5
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 5
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims abstract description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 5
- 238000000746 purification Methods 0.000 claims abstract description 5
- 102000004411 Antithrombin III Human genes 0.000 claims abstract description 4
- 108090000935 Antithrombin III Proteins 0.000 claims abstract description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000004472 Lysine Substances 0.000 claims abstract description 4
- 229930195725 Mannitol Natural products 0.000 claims abstract description 4
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 claims abstract description 4
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 claims abstract description 4
- 235000001014 amino acid Nutrition 0.000 claims abstract description 4
- 229960005348 antithrombin iii Drugs 0.000 claims abstract description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 4
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims abstract description 4
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 4
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 4
- 239000008139 complexing agent Substances 0.000 claims abstract description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000018417 cysteine Nutrition 0.000 claims abstract description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims abstract description 4
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000012530 fluid Substances 0.000 claims abstract description 4
- 239000008103 glucose Substances 0.000 claims abstract description 4
- 229930195712 glutamate Natural products 0.000 claims abstract description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 4
- 239000000594 mannitol Substances 0.000 claims abstract description 4
- 235000010355 mannitol Nutrition 0.000 claims abstract description 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract description 4
- 235000000346 sugar Nutrition 0.000 claims abstract description 4
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims abstract description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims abstract description 4
- 108010088751 Albumins Proteins 0.000 claims abstract description 3
- 102000009027 Albumins Human genes 0.000 claims abstract description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 102100037362 Fibronectin Human genes 0.000 claims abstract description 3
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 3
- 108010010803 Gelatin Proteins 0.000 claims abstract description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims abstract description 3
- 150000001298 alcohols Chemical class 0.000 claims abstract description 3
- 239000000427 antigen Substances 0.000 claims abstract description 3
- 108091007433 antigens Proteins 0.000 claims abstract description 3
- 102000036639 antigens Human genes 0.000 claims abstract description 3
- 239000003599 detergent Substances 0.000 claims abstract description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims abstract description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229920000159 gelatin Polymers 0.000 claims abstract description 3
- 239000008273 gelatin Substances 0.000 claims abstract description 3
- 235000019322 gelatine Nutrition 0.000 claims abstract description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 3
- 229960002591 hydroxyproline Drugs 0.000 claims abstract description 3
- 108010093564 inter-alpha-inhibitor Proteins 0.000 claims abstract description 3
- 229920000136 polysorbate Polymers 0.000 claims abstract description 3
- 239000002904 solvent Substances 0.000 claims abstract description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract 2
- 235000019419 proteases Nutrition 0.000 claims description 78
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 7
- 150000001450 anions Chemical class 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 6
- 229940012413 factor vii Drugs 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- 239000012876 carrier material Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 230000015271 coagulation Effects 0.000 claims description 3
- 238000005345 coagulation Methods 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 241001631457 Cannula Species 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 2
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 2
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 claims description 2
- 239000013060 biological fluid Substances 0.000 claims description 2
- 230000023555 blood coagulation Effects 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 238000013375 chromatographic separation Methods 0.000 claims description 2
- 229940105772 coagulation factor vii Drugs 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 210000003709 heart valve Anatomy 0.000 claims description 2
- 239000002607 heparin antagonist Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000012622 synthetic inhibitor Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000001732 thrombotic effect Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 claims 1
- 235000021405 artificial diet Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229940105776 factor viii inhibitor bypassing activity Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 101001035951 Homo sapiens Hyaluronan-binding protein 2 Proteins 0.000 abstract description 4
- 102100039238 Hyaluronan-binding protein 2 Human genes 0.000 abstract description 4
- 150000001413 amino acids Chemical class 0.000 abstract description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 abstract description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract description 2
- 108020004511 Recombinant DNA Proteins 0.000 abstract 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 abstract 1
- 102100035140 Vitronectin Human genes 0.000 abstract 1
- 108010031318 Vitronectin Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- -1 glycine; sugars Chemical class 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 description 74
- 230000000694 effects Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 108010001014 Plasminogen Activators Proteins 0.000 description 5
- 102000001938 Plasminogen Activators Human genes 0.000 description 5
- 229940127126 plasminogen activator Drugs 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 108010073863 saruplase Proteins 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000016519 Coagulation factor VII Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
- 101000892112 Oxyuranus scutellatus Venom prothrombin activator oscutarin-C catalytic subunit Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000005966 endogenous activation Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 230000005968 exogenous activation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000020971 positive regulation of blood coagulation Effects 0.000 description 1
- 230000031915 positive regulation of coagulation Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000007281 self degradation Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19937219A DE19937219A1 (de) | 1999-08-06 | 1999-08-06 | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie |
| ES00114370T ES2298110T3 (es) | 1999-08-06 | 2000-07-05 | Procedimiento para la preparacion en estado puro de la proenzima de la proteasa que activa el factor de coagulacion vii mediante cromatografia de intercambio de iones. |
| EP00114370A EP1074616B1 (de) | 1999-08-06 | 2000-07-05 | Verfahren zur Reindarstellung des Proenzyms der den Blutgerinnungsfaktor VII aktivierenden Protease mittels Ionenaustauscherchromatographie |
| DE50014975T DE50014975D1 (de) | 1999-08-06 | 2000-07-05 | Verfahren zur Reindarstellung des Proenzyms der den Blutgerinnungsfaktor VII aktivierenden Protease mittels Ionenaustauscherchromatographie |
| AT00114370T ATE386798T1 (de) | 1999-08-06 | 2000-07-05 | Verfahren zur reindarstellung des proenzyms der den blutgerinnungsfaktor vii aktivierenden protease mittels ionenaustauscherchromatographie |
| CA002315306A CA2315306A1 (en) | 1999-08-06 | 2000-08-03 | Process for the preparation in pure form of the protease activating blood clotting factor vii, its proenzyme or a mixture of both proteins by means of ion-exchange chromatography |
| AU51838/00A AU781741B2 (en) | 1998-04-24 | 2000-08-04 | Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or mixture of both proteins by means of ion-exchange chromatography |
| US09/632,627 US6677440B1 (en) | 1999-08-06 | 2000-08-04 | Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins by means of ion-exchange chromatography |
| JP2000236804A JP2001095563A (ja) | 1999-08-06 | 2000-08-04 | イオン交換クロマトグラフィーによって血液凝固第ｖｉｉ因子を活性化するプロテアーゼ、そのプロ酵素または両タンパク質の混合物を純粋形態で調製する方法 |
| KR1020000045200A KR20010049988A (ko) | 1999-08-06 | 2000-08-04 | 이온 교환 크로마토그래피에 의한 순수형 프로테아제활성화 혈액 응고 인자 ⅶ, 이의 전효소 또는 이들 단백질둘 다의 혼합물의 제조방법 |
| AU51837/00A AU781717B2 (en) | 1998-04-24 | 2000-08-04 | Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or mixture of both proteins by means of ion-exchange chromatography |
| US10/701,671 US20040186277A1 (en) | 1999-08-06 | 2003-11-06 | Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins by means of ion-exchange chromatography |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19937219A DE19937219A1 (de) | 1999-08-06 | 1999-08-06 | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19937219A1 true DE19937219A1 (de) | 2001-02-08 |
Family
ID=7917489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19937219A Withdrawn DE19937219A1 (de) | 1998-04-24 | 1999-08-06 | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie |
| DE50014975T Expired - Lifetime DE50014975D1 (de) | 1999-08-06 | 2000-07-05 | Verfahren zur Reindarstellung des Proenzyms der den Blutgerinnungsfaktor VII aktivierenden Protease mittels Ionenaustauscherchromatographie |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50014975T Expired - Lifetime DE50014975D1 (de) | 1999-08-06 | 2000-07-05 | Verfahren zur Reindarstellung des Proenzyms der den Blutgerinnungsfaktor VII aktivierenden Protease mittels Ionenaustauscherchromatographie |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6677440B1 (https=) |
| EP (1) | EP1074616B1 (https=) |
| JP (1) | JP2001095563A (https=) |
| KR (1) | KR20010049988A (https=) |
| AT (1) | ATE386798T1 (https=) |
| CA (1) | CA2315306A1 (https=) |
| DE (2) | DE19937219A1 (https=) |
| ES (1) | ES2298110T3 (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6831167B2 (en) | 2000-07-26 | 2004-12-14 | Aventis Behring Gmbh | Mutants of the factor VII-activating protease and detection methods using specific antibodies |
| US7153679B2 (en) | 2000-07-26 | 2006-12-26 | Aventis Behring Gmbh | Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis |
| US7829095B2 (en) | 2002-02-08 | 2010-11-09 | Csl Behring Gmbh | Inhibitory monoclonal antibody against blood clotting factor VII-activating protease |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19903693A1 (de) * | 1998-04-24 | 1999-10-28 | Centeon Pharma Gmbh | Protease zur Aktivierung des Gerinnungsfaktors VII |
| DE10023923A1 (de) * | 1999-06-10 | 2000-12-14 | Aventis Behring Gmbh | Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen |
| JP4005338B2 (ja) * | 2000-11-29 | 2007-11-07 | ペンタックス株式会社 | 抗体固相化担体、および、その製造方法 |
| US20020114800A1 (en) | 2000-11-29 | 2002-08-22 | Asahi Kogaku Kogyo Kabushiki Kaisha | Carrier having immobilized antigens or antibodies and method of manufacturing thereof |
| DE10148037A1 (de) * | 2001-09-28 | 2003-04-17 | Aventis Behring Gmbh | Verwendung der den Blutgerinnungsfaktor VII aktivierenden Protease zur Prophylaxe und Therapie von vaso-proliferativen Erkrankungen |
| AU2003232315A1 (en) * | 2002-05-07 | 2003-11-11 | Medical Research Council | Sarcosyl buffer and its use for the purification of prion protein |
| KR100508606B1 (ko) * | 2002-11-15 | 2005-08-17 | 주식회사 바이오세움 | 효소 안정화 조성물 및 상기 조성물을 이용한 효소 보관방법 |
| RU2364626C2 (ru) * | 2003-03-18 | 2009-08-20 | Ново Нордиск Хелт Кэр Аг | Способ получения, способ очистки и способ стабилизации полипептидов фактора vii, ix и x |
| WO2008031020A2 (en) * | 2006-09-08 | 2008-03-13 | Wyeth | Arginine wash in protein purification using affinity chromatography |
| US7705132B2 (en) * | 2006-10-20 | 2010-04-27 | Amgen Inc. | Stable polypeptide formulations |
| BRPI0810172A2 (pt) | 2007-04-13 | 2014-10-14 | Catalyst Biosciences Inc | Polipeptídeos de fator vii modificado e seus usos |
| JP5119545B2 (ja) * | 2007-06-19 | 2013-01-16 | 国立大学法人 筑波大学 | 蛋白質を含む液状組成物中における蛋白質の安定化方法 |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| CA2821711C (en) | 2010-12-15 | 2017-10-10 | Baxter International Inc. | Eluate collection using conductivity gradient |
| EP2729570B1 (en) | 2011-07-04 | 2017-11-22 | Qiagen GmbH | Reagent usable for the isolation and/or purification of nucleic acids |
| GB2504499A (en) * | 2012-07-31 | 2014-02-05 | Baxter Healthcare Sa | Selective measurement of active human protease coagulation factors |
| KR102382402B1 (ko) | 2014-02-04 | 2022-04-01 | 바이오젠 엠에이 인코포레이티드 | 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도 |
| WO2021030787A1 (en) | 2019-08-15 | 2021-02-18 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL87276A (en) * | 1987-08-03 | 1995-07-31 | Fujisawa Pharmaceutical Co | Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same |
| DE19903693A1 (de) * | 1998-04-24 | 1999-10-28 | Centeon Pharma Gmbh | Protease zur Aktivierung des Gerinnungsfaktors VII |
| DE19937218A1 (de) * | 1999-08-06 | 2001-02-08 | Aventis Behring Gmbh | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie |
-
1999
- 1999-08-06 DE DE19937219A patent/DE19937219A1/de not_active Withdrawn
-
2000
- 2000-07-05 EP EP00114370A patent/EP1074616B1/de not_active Expired - Lifetime
- 2000-07-05 DE DE50014975T patent/DE50014975D1/de not_active Expired - Lifetime
- 2000-07-05 AT AT00114370T patent/ATE386798T1/de active
- 2000-07-05 ES ES00114370T patent/ES2298110T3/es not_active Expired - Lifetime
- 2000-08-03 CA CA002315306A patent/CA2315306A1/en not_active Abandoned
- 2000-08-04 JP JP2000236804A patent/JP2001095563A/ja active Pending
- 2000-08-04 KR KR1020000045200A patent/KR20010049988A/ko not_active Abandoned
- 2000-08-04 US US09/632,627 patent/US6677440B1/en not_active Expired - Fee Related
-
2003
- 2003-11-06 US US10/701,671 patent/US20040186277A1/en not_active Abandoned
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6831167B2 (en) | 2000-07-26 | 2004-12-14 | Aventis Behring Gmbh | Mutants of the factor VII-activating protease and detection methods using specific antibodies |
| US7153679B2 (en) | 2000-07-26 | 2006-12-26 | Aventis Behring Gmbh | Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis |
| US7442514B2 (en) | 2000-07-26 | 2008-10-28 | Csl Behring Gmbh | Mutants of the factor VII-activating protease and detection methods using specific antibodies |
| US7803569B2 (en) | 2000-07-26 | 2010-09-28 | Csl Behring Gmbh | Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutations |
| US7863009B2 (en) | 2000-07-26 | 2011-01-04 | Csl Behring Gmbh | Mutants of the factor VII-activating protease and detection methods using specific antibodies |
| US7829095B2 (en) | 2002-02-08 | 2010-11-09 | Csl Behring Gmbh | Inhibitory monoclonal antibody against blood clotting factor VII-activating protease |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2298110T3 (es) | 2008-05-16 |
| EP1074616B1 (de) | 2008-02-20 |
| US6677440B1 (en) | 2004-01-13 |
| ATE386798T1 (de) | 2008-03-15 |
| CA2315306A1 (en) | 2001-02-06 |
| DE50014975D1 (de) | 2008-04-03 |
| JP2001095563A (ja) | 2001-04-10 |
| EP1074616A1 (de) | 2001-02-07 |
| KR20010049988A (ko) | 2001-06-15 |
| US20040186277A1 (en) | 2004-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1074616B1 (de) | Verfahren zur Reindarstellung des Proenzyms der den Blutgerinnungsfaktor VII aktivierenden Protease mittels Ionenaustauscherchromatographie | |
| DE19937218A1 (de) | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie | |
| EP0181465B1 (de) | Blutgerinnungshemmende Proteine, Verfahren zur Herstellung sowie deren Verwendung | |
| DE68915675T3 (de) | Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen. | |
| DE3586402T2 (de) | Proteinzusammensetzung mit koagulations-wirkung und verfahren zu ihrer herstellung. | |
| AT407115B (de) | Verfahren zur herstellung eines konzentrates von standardisiertem, menschlichem von willebrand-faktor | |
| DE69930778T2 (de) | Protease zum Aktivierung des Gerinnungsfaktor VII | |
| DE2734821C3 (de) | Blutgerinnungsfördernde Präparation und Verfahren zu ihrer Herstellung | |
| EP0244834B1 (de) | Verfahren zur Herstellung eines Faktor V-Konzentrats | |
| AT399095B (de) | Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens | |
| EP0409053B1 (de) | Verfahren zur Reinigung von Annexinen | |
| EP0770625B1 (de) | Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII | |
| DE2734427C3 (de) | Verfahren zur Gewinnung von thrombinartigen Enzymen aus Schlangengiften | |
| EP1012191B1 (de) | VERFAHREN ZUR GEWINNUNG VON HOCHREINEM vWF ODER FACTOR VIII/vWF-KOMPLEX | |
| DE4406515C1 (de) | Verfahren zur Isolierung und Reinigung Vitamin K-abhängiger Proteine | |
| DE2924744A1 (de) | Verfahren zur reindarstellung von urokinase | |
| EP0049861B1 (de) | Thrombininhibitor, seine Herstellung und Verwendung | |
| AU781741B2 (en) | Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or mixture of both proteins by means of ion-exchange chromatography | |
| DE69009667T2 (de) | Verfahren zur Herstellung von Protease-Inhibitoren. | |
| EP0910629B1 (de) | Verfahren zur Herstellung einer Antidotausgangssubstanz für natürliche und synthetische Thrombininhibitoren | |
| DE3804590A1 (de) | Diagnostische sonden zum nachweis von elastase-modifiziertem antithrombin und verfahren zur behandlung | |
| WO1998040474A2 (de) | Aktivierter vitamin k-abhängiger blutfaktor und verfahren zu dessen herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: ZLB BEHRING GMBH, 35041 MARBURG, DE |
|
| 8110 | Request for examination paragraph 44 | ||
| 8127 | New person/name/address of the applicant |
Owner name: CSL BEHRING GMBH, 35041 MARBURG, DE |
|
| 8130 | Withdrawal |